– ABI-6250’s pharmacodynamic analysis was recognized as a Poster of Distinction –

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced that two posters featuring new Phase 1a data from its ABI-6250 program will be presented at The Liver Meeting® 2026, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 5-9, 2026, in Denver, Colorado.

“The Phase 1a findings support ABI-6250’s safety profile and demonstrate potent target engagement, and we are pleased the pharmacodynamic analysis was recognized as a Poster of Distinction,” said Anuj Gaggar, M.D., Ph.D., chief medical officer of Assembly Bio. “We look forward to sharing these results with the hepatology community as we prepare to advance ABI-6250 into Phase 2 studies in both chronic HDV infection and cholestatic liver diseases.”

The presentations will include safety, tolerability and pharmacodynamic findings from the randomized, blinded Phase 1a study of ABI-6250 in healthy participants. ABI-6250 was well tolerated at the doses evaluated, with no serious adverse events reported, and demonstrated dose-dependent, reversible increases in total and conjugated bile acids consistent with sodium taurocholate co-transporting polypeptide (NTCP) target engagement. The Phase 1a findings support Assembly Bio’s plans to initiate Phase 2 studies in patients with chronic hepatitis delta virus (HDV) infection in the fourth quarter of 2026 and in patients with cholestatic liver diseases, focused on primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), in the first quarter of 2027.

Details of the presentations are as follows:

Poster of Distinction Title: Oral NTCP Inhibitor ABI-6250 Elevates Bile Acids in a Randomized, Blinded, Phase 1a Study in Healthy Subjects
Presenter: Edward J. Gane, MD, FAASLD, University of Auckland
Publication Number: 3197

  • Session: Hepatitis – Other Infections
  • Date and Time: November 7, 2026; 1:00 – 2:00 p.m. MT

Poster Title: The Safety and Tolerability of ABI-6250, an Orally Administered NTCP Inhibitor in Healthy Participants
Presenter: Edward J. Gane, MD, FAASLD, University of Auckland
Publication Number: 3204

  • Session: Hepatitis – Other Infections
  • Date and Time: November 7, 2026; 1:00 – 2:00 p.m. MT

Assembly Bio intends to make the posters available on the “Events & Presentations” page in the “Investors” section and on the “Publications” page in the “Pipeline” section of its website at www.assemblybio.com.

About ABI-6250
ABI-6250 is an investigational oral small-molecule inhibitor of the sodium taurocholate co-transporting polypeptide (NTCP), a membrane protein selectively expressed on hepatocytes that facilitates bile acid transport into cells and also serves as the receptor for hepatitis B virus (HBV) and hepatitis delta virus (HDV) to enter hepatocytes. Assembly Bio is developing ABI-6250 for the treatment of chronic HDV infection, where the targeting of NTCP blocks viral infection and is a clinically validated mechanism. ABI-6250 is also being evaluated in cholestatic liver diseases, such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), where bile acid accumulation in the liver drives liver inflammation and liver injury. The targeting of NTCP by ABI-6250 blocks the uptake of bile acids into liver cells.

About Assembly Biosciences
Assembly Biosciences is a biotechnology company developing innovative small-molecule therapeutics aimed at advancing the treatment paradigm of serious viral and liver diseases and improving the lives of patients worldwide. Led by an accomplished leadership team in antiviral and liver disease drug development, Assembly Bio is committed to improving outcomes for people living with the chronic impacts of herpesvirus, hepatitis delta virus (HDV) infections, cholestatic liver diseases and hepatitis B virus (HBV). For more information, visit assemblybio.com.

Forward-Looking Statements
The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to realize the potential benefits of its collaboration with Gilead, including all financial aspects of the collaboration and equity investments; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration with Gilead, including studies conducted by Gilead, in the currently anticipated timeframes or at all; safety and efficacy data from clinical or nonclinical studies may not warrant further development of product candidates; clinical and nonclinical data may not differentiate product candidates from other companies’ candidates; Assembly Bio’s ability to maintain financial resources and secure additional funding necessary to continue its research activities, clinical studies, and other business operations; potential effects of changes in government regulation; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Investors:
Patrick Till
Meru Advisors
(484) 788-8560
investor_relations@assemblybio.com

Media:
Mike Beyer
Sam Brown LLC
(312) 961-2502 
ASMBMedia@sambrown.com

Maranello (Italy), October 5, 2026 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 250 million share buyback program announced on September 1, 2026, as the third tranche of the multi-year share buyback program of approximately Euro 3.5 billion expected to be executed by 2030 in line with the disclosure made during the 2025 Capital Markets Day (the “Third Tranche”), the additional common shares – reported in aggregate form, on a daily basis – on the Euronext Milan (EXM) and on the New York Stock Exchange (NYSE) as follows:

  EXM NYSE Total
Trading Number of common shares purchased

Average price per share Consideration excluding fees Number of common shares purchased

Average price per share Consideration excluding fees Consideration excluding fees Number of common shares purchased

Average price per share Consideration excluding fees
Date excluding fees   excluding fees     excluding fees  
(d/m/y) (€) (€) ($) ($) (€)* (€)* (€)*
               
28/09/2026 12,000 353.0071 4,236,085.20 12,598 396.8864 4,999,974.87 4,394,423.33 24,598 350.8622 8,630,508.53
29/09/2026 6,000 352.6159 2,115,695.40 – – – – 6,000 352.6159 2,115,695.40
30/09/2026 15,000 348.8100 5,232,150.00 11,436 393.4633 4,499,646.30 3,962,700.40 26,436 347.8155 9,194,850.40
01/10/2026 9,000 345.2410 3,107,169.00 – – – – 9,000 345.2410 3,107,169.00
02/10/2026 7,500 345.2934 2,589,700.50 – – – – 7,500 345.2934 2,589,700.50
  49,500

349.1071

17,280,800.10

24,034

395.2576

9,499,621.17

8,357,123.73

73,534

348.6540

25,637,923.83

Total
 

(*) translated at the European Central Bank EUR/USD exchange reference rate as of the date of each purchase
        
Since the announcement of such Third Tranche till October 2, 2026, the total invested consideration has been:

  • Euro 74,735,928.03 for No. 210,299 common shares purchased on the EXM
  • USD 31,498,189.59 (Euro 27,457,608.48*) for No. 77,824 common shares purchased on the NYSE.

As of October 2, 2026 the Company held in treasury No. 1,878,927 common shares, net of shares assigned under the Company’s equity incentive plan, corresponding to 1.06% of the then total issued common shares. Including the special voting shares, the Company held in treasury 0.80% of the then total issued share capital.
Since January 5, 2026, start date of the multi-year share buyback program of approximately Euro 3.5 billion announced during the 2025 Capital Markets Day, until October 2, 2026, the Company has purchased a total of 1,989,307 own common shares on EXM and NYSE, including transactions for Sell to Cover, for a total consideration of Euro 612,950,841.72.

A comprehensive overview of the transactions carried out under the buyback program, as well as the details of the above transactions, are available on Ferrari’s corporate website under the Buyback Programs section (https://www.ferrari.com/en-EN/corporate/buyback-programs).

For further information:
Ferrari Media & PR
Email: media@ferrari.com

Attachment

JERUSALEM, Oct. 05, 2026 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that company management will participate in the following investor conferences in October 2026.

Event: Fall Focus: Barclays Biotech 1×1 Day
Format: 1×1 Meetings
Date: Tuesday, October 6, 2026
Location: New York, NY

  

Event: Investment Generation Conference
Format: Presentation
Date: Thursday, October 15, 2026
Time: 12:30 – 1:00 PM
Location: Rishon Letzion, Israel


About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

About Alpha DaRT®

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

Investor Relations Contact:

IR@alphatau.com

Tsang joins AIBotics as Strategic Advisor ahead of contemplated CEO and director appointment upon closing, as Company moves to acquire the U.S.-focused Empulser defense-technology platform.

MIAMI, Oct. 05, 2026 (GLOBE NEWSWIRE) — AIBotics, Inc. (OTCID: AIBT) (“AIBotics” or the “Company”), a public company focused on AI-enabled robotics, intelligent automation and emerging technology, today announced that on October 2, 2026 it entered into an Agreement for the Exchange of Stock (the “Exchange Agreement”) with Empulser Enterprises LLC (“Empulser”), a Wyoming limited liability company founded by Patrick Tsang, and the members of Empulser. Upon closing, AIBotics will acquire 100% of the issued and outstanding membership interests of Empulser, and Empulser will become a wholly owned subsidiary of AIBotics. In connection with the transaction and the Company’s next phase of strategic growth, Tsang has joined AIBotics as a Strategic Advisor.

The agreement brings Tsang and Empulser to the center of AIBotics’ evolving public-company strategy. Empulser is being developed around the convergence of wireless power, autonomous systems, AI-enabled unmanned technologies and the infrastructure required to support more persistent autonomous operations. The proposed acquisition is intended to provide a public-market platform through which Empulser can pursue technology development, intellectual-property expansion, testing and validation, capitalization, strategic relationships and, ultimately, commercial and defense applications.

Patrick Tsang Brings a New Technology Platform to AIBotics

Tsang brings more than two decades of experience across global capital markets, public-company transactions, mergers and acquisitions, strategic investing, corporate development and emerging technology. As Strategic Advisor to AIBotics, he is expected to work with Chief Executive Officer Ben Kaplan and the Company on strategic growth, capital-markets strategy, corporate development, international partnerships and the identification of opportunities across AI, robotics, autonomous systems and related technologies.

Tsang is Chairman of Tsang Group, a fourth-generation single family office with interests across technology, real estate and natural resources. Over more than two decades, he has worked across international investment, capital formation, mergers and acquisitions, corporate development and emerging technology, building relationships across Asia, Europe, the Middle East and North America. He is also the Founder and Chief Executive Officer of Empulser, the defense and dual-use technology platform that AIBotics has agreed to acquire.

A Public-Market Track Record

Under Patrick Tsang’s leadership, an early-stage investment was made in Pulse Evolution Group in 2018, alongside a strategic advisory role. Pulse subsequently became part of FaceBank Group, which completed its merger with fuboTV in 2020, culminating in fuboTV trading on the New York Stock Exchange during the Covid period.

Empulser: Defense, Autonomy and the Infrastructure Behind Intelligent Machines

Empulser is focused on building a U.S. defense and dual-use technology platform around wireless power and autonomous systems. Its development strategy centers on technologies intended to address a fundamental challenge facing unmanned platforms: extending operational endurance while reducing dependence on manual charging and support infrastructure. Empulser’s broader vision includes wireless power transfer, autonomous aerial and ground systems, AI-enabled mission functionality and infrastructure designed to support unmanned operations across defense, government, critical-infrastructure and commercial environments.

Empulser remains in a development and commercialization phase. Future technology, product, testing, certification, customer and revenue milestones will be announced only as they are achieved and can be substantiated. AIBotics and Empulser intend to build public communications around documented execution rather than projected milestones.

Transaction Overview

Under the Exchange Agreement, AIBotics will acquire 100% of the issued and outstanding membership interests of Empulser from the Empulser Members in exchange for up to 2,200,000 shares of a newly designated Series C Preferred Stock having an aggregate stated value of up to $22.0 million. The Certificate of Designation provides for an original issue price of $10.00 per share. Of the total acquisition consideration, 220,000 shares, representing 10%, are allocated to the closing and 198,000, representing 9%, shares are allocated to each of ten separate earn-out milestones.

The earn-out period begins at closing and continues for 36 months. The milestones cover specified patent filings and issuances, product demonstration and flight testing, acceptance into a formal test, evaluation or pilot program, and achievement of $500,000 in cumulative recognized revenue. Shares tied to a milestone are earned only if that milestone is achieved during the earn-out period; unearned milestone shares will cease to be issuable or will be forfeited and cancelled, as applicable under the Exchange Agreement.

The Series C Preferred Stock pays no dividends and generally has no voting rights except as provided in the Certificate of Designation or required by law. Each share is convertible at the holder’s option into AIBotics common stock under the formula set forth in the Certificate of Designation. The initial conversion price will equal the closing price of AIBotics common stock on its principal market on the trading day immediately preceding the transaction closing, subject to specified adjustments. Conversion is subject to certain beneficial-ownership limitations, subject to the notice and waiver provisions described in the Certificate of Designation.

AIBotics may, in its sole discretion, advance up to $2.0 million to Empulser before closing for expenditures under an approved budget. Any advances will be structured as loans secured by a first-priority security interest in all of Empulser’s assets and will be subject to the promissory note and related security documents to be negotiated.

Closing is subject to customary and transaction-specific conditions, including the transfer of 100% of Empulser’s membership interests, compliance with the parties’ covenants and representations, delivery by Empulser of audited financial statements for the periods required by Regulation S-X prepared in accordance with U.S. GAAP, and AIBotics being current in its SEC and/or OTC Markets filing obligations and labeled “Current” on OTC Markets. The Exchange Agreement provides for termination in specified circumstances if the transaction has not closed within 90 days after October 2, 2026 or if applicable closing conditions have not been satisfied or waived by January 2, 2027. There can be no assurance that the transaction will close.

As disclosed in the Form 8-K, Tsang is to provide consulting and advisory services regarding AIBotics’ existing business for 90 days or until a chief executive officer agreement becomes effective. Subject to applicable law, a satisfactory background and eligibility review, approval by AIBotics’ Board of Directors in the exercise of its fiduciary duties, and execution of a satisfactory CEO agreement, AIBotics intends to appoint Tsang as Chief Executive Officer and a director effective upon closing of the Empulser acquisition.

The foregoing is a summary of selected transaction terms. Additional information regarding the Exchange Agreement, the Series C Preferred Stock, the closing conditions and the proposed transaction is contained in AIBotics’ Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission, including the Exchange Agreement filed as Exhibit 10.1. The full agreement and filed disclosure should be reviewed for a complete description of the transaction.

Management Commentary

Ben Kaplan, Chief Executive Officer of AIBotics, said, “This is an important step in the evolution of AIBotics. Patrick brings a rare combination of global capital-markets experience, public-company transaction expertise, technology investing, corporate development and international relationships — and he has built Empulser around technologies that fit directly into where we believe AI and autonomous systems are heading. The definitive agreement gives us a potential foundation for building a much broader defense and dual-use technology platform. Patrick’s experience identifying emerging opportunities, attracting capital, developing strategic relationships and navigating public markets can be extremely valuable as we move into this next phase.”

Patrick Tsang said, “This transaction marks an important new chapter for Empulser. We believe the opportunity in autonomous systems is much broader than building another drone or robot. The real challenge is enabling intelligent machines to operate for longer, with greater resilience and less human intervention. Empulser is being built around that challenge — combining wireless power, autonomous systems and enabling technologies to increase the persistence and effectiveness of unmanned platforms. Working with Ben and the AIBotics team gives us a public-market platform from which to develop the technology, attract world-class partners and capital, and build a significant U.S. defense and dual-use technology company.”

During the pre-closing period, Tsang’s advisory role is expected to include strategic growth, capital formation, public-market strategy, corporate development, international partnerships and the evaluation of complementary emerging technologies and acquisition opportunities. As disclosed in the Form 8-K, following the closing of the acquisition of Empulser, AIBotics also intends, subject to the conditions described in the Exchange Agreement, to appoint Tsang as Chief Executive Officer and a director. The Company expects to provide additional updates as the Empulser transaction progresses and as material operating milestones are achieved.

About AIBotics

AIBotics, Inc. is a global technology company building a platform around AI-enabled robotics, autonomous systems and intelligent automation. The Company focuses on applying advanced technologies to real-world environments through strategic partnerships, technology development and international market relationships. AIBotics seeks to identify, develop, implement and scale solutions that improve how machines operate, automate business processes and extend the practical application of artificial intelligence into the physical world. Through a scalable, partnership-driven model, AIBotics is building a diversified robotics and autonomous-systems platform designed to support commercial, industrial and other mission-driven applications across global markets. For more information on AIBotics, visit www.aibotics.ai

About Empulser Enterprises LLC

Empulser Enterprises LLC is a U.S.-focused defense and dual-use technology company developing a platform around wireless power, autonomous systems, unmanned technologies and supporting infrastructure. Empulser’s development strategy is focused on technologies intended to improve the endurance, deployment and coordination of autonomous platforms across defense, government, critical-infrastructure and commercial applications. Empulser’s products and technologies are in development, and future milestones are subject to successful engineering, testing, validation, certification, funding and commercialization. For more information on Empulser, visit www.empulser.com.

About Patrick Tsang

Patrick Tsang is an international investor and entrepreneur and Chairman of Tsang Group, a fourth-generation single family office with interests across technology, real estate and natural resources. He is the Founder and Chief Executive Officer of Empulser Enterprises LLC, a U.S.-focused defense and dual-use technology company developing technologies around wireless power, autonomous systems and unmanned platforms.

Over more than two decades, Tsang has worked across international investment, capital formation, mergers and acquisitions, corporate development and emerging technology, building relationships across Asia, Europe, the Middle East and North America. Through his leadership, he was an early-stage investor and strategic advisor to Pulse Evolution, helping guide its journey through the FaceBank/fuboTV transaction to fuboTV’s listing on the New York Stock Exchange during the Covid period. SEC filings subsequently referenced an approximately 300-times return in two years on the investment based on fuboTV’s late-2020 share price.

Tsang is a qualified solicitor in England and Wales and Hong Kong and attended Harvard Business School’s Owner/President Management (OPM) program. He is the author of The Global Citizen and has been actively involved in philanthropy and international leadership throughout his career, including through the Duke of Edinburgh’s World Fellowship, Rotary International and YPO. He was recognized as China Economic Person of the Year during the China Economic Development Forum in 2014.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements include, among other things, statements regarding the proposed acquisition of Empulser; the anticipated structure, timing, closing and benefits of the transaction; the issuance, earning and conversion of Series C Preferred Stock and potential dilution associated with conversion; the achievement and verification of earn-out milestones; any discretionary pre-closing loans by AIBotics to Empulser; the contemplated management transition involving Patrick Tsang; AIBotics’ and Empulser’s business strategies; technology development, testing, validation, certification and commercialization; intellectual-property development; financing and capital formation; strategic partnerships; government, defense and commercial opportunities; potential customers, contracts and revenue; future acquisitions; and the Company’s broader strategy in AI, robotics, autonomous systems and defense and dual-use technology. Forward-looking statements are based on current expectations, assumptions and estimates and are subject to risks and uncertainties that could cause actual results to differ materially. These risks include, among others, the possibility that the transaction may not close on the anticipated terms or timing, or at all; failure to satisfy or waive closing conditions, including delivery of required audited financial statements and maintenance of required filing status; termination following due diligence, an uncured material breach or a material adverse change; AIBotics’ decision not to provide discretionary pre-closing financing or the parties’ failure to execute satisfactory loan and security documents; failure to achieve or substantiate earn-out milestones; setoff or cancellation of earn-out consideration; dilution associated with conversion of preferred stock; failure to satisfy the conditions to Patrick Tsang’s proposed appointment as Chief Executive Officer and a director; integration risks; development and engineering risks; testing, certification and regulatory requirements; protection of intellectual property; competition; dependence on key personnel and strategic relationships; customer adoption; government procurement processes; and the Company’s ability to execute its business plan. Readers should review AIBotics’ filings with the U.S. Securities and Exchange Commission, including the Current Report on Form 8-K relating to the Exchange Agreement, for additional information concerning risks and uncertainties. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update them except as required by law.

Media and Investor Relations

David Kugelman
Atlanta Capital Partners, LLC
(404) 856-9157 Office
(404) 281-8556 Mobile and WhatsApp
dk@atlcp.com

Strategic connectivity relationship helps support resilient operations across Caesars Superdome and Saints facilities while enhancing the experience for fans, staff, partners and business stakeholders

NEW ORLEANS, Oct. 05, 2026 (GLOBE NEWSWIRE) — Uniti Fiber, a leading fiber infrastructure provider, and the New Orleans Saints today announced a partnership to provide scalable, high-capacity fiber connectivity supporting critical business operations, venue systems and connected experiences across the Saints organization, including periods of elevated demand.

As sports and entertainment venues increasingly depend on reliable, high-capacity networks to power everything from gameday operations to business applications, Uniti Fiber will help support connectivity across Caesars Superdome and other Saints facilities. The relationship is designed to strengthen operational resilience, improve continuity for critical systems and enable the connected experiences fans, employees, partners and guests expect on gameday and throughout the year.

“Reliable, high-performance connectivity is essential to every part of our organization, from providing our coaching staff and football operations personnel with the tools they need to supporting daily business functions and delivering the experience our fans expect on gameday,” said Jody Barbier, New Orleans Saints vice president of Information Technology. “In a business where preparation, precision and real-time communication are critical, having a first-class network is vital. Our partnership with Uniti Fiber strengthens that foundation and gives us the capacity and flexibility to meet our technology needs as they evolve.”

Fiber infrastructure provides the speed, capacity and reliability required to support the Saints’ technology ecosystem from secure business systems and point-of-sale activity to media workflows and real-time communications. Uniti Fiber’s scalable network helps create a resilient foundation for evolving operational needs and connected fan experiences.

“The Saints operate in an environment where dependable connectivity is critical every day, not only on gameday,” said Megan Meyer, regional vice president for Uniti Fiber. “We’re proud to bring our local fiber expertise and commitment to reliability to one of Louisiana’s most iconic organizations, helping provide the scalable foundation it needs to serve employees, partners and fans with confidence.”

The partnership builds on Uniti Fiber’s continued investment in Louisiana, where its high-capacity fiber network supports businesses, healthcare organizations, government entities and other operations that depend on reliable connectivity.

Beyond connectivity and operational excellence, the partnership reflects a shared commitment to the communities both organizations serve. The New Orleans Saints have long been leaders in supporting military members, veterans and their families throughout the Gulf South, and Uniti Fiber is proud to partner with organizations that invest in the people and communities that make Louisiana strong. Together, the organizations are helping strengthen connections not only through technology, but through a shared commitment to service, resilience and community impact across the region.

Through the partnership, the Saints and Uniti Fiber are establishing a resilient connectivity foundation designed to support evolving business operations, venue technology and connected experiences for years to come.

About Uniti Fiber

Uniti Fiber, a business unit of Uniti Group Inc. (NASDAQ: UNIT), delivers customized, always-on enterprise-grade fiber, ethernet, dark fiber, voice and unified communications, colocation and a suite of managed connectivity solutions reaching more than 375,000 business, state and local government and education locations in 35 markets across six states in the Southeastern U.S. Additional information about Uniti Fiber is available at uniti.com. Engage with us on LinkedIn.

Uniti Contact:
Scott Morris, 501-748-5342
scott.l.morris@uniti.com
        

Acquisition Adds an Established Subscription-Based Food Commerce Business, Recurring Revenue Model and Proprietary Technology Platform to Tritent’s Growing Portfolio

LAS VEGAS, Oct. 05, 2026 (GLOBE NEWSWIRE) — Tritent International Corp. (OTCID: TICJ) (“Tritent” or the “Company”) today announced that its wholly owned Ontario subsidiary has entered into a definitive agreement to acquire 100% of the issued and outstanding shares of Super Fresh Foods Inc., owner and operator of AllYourMeals.com, a subscription-based prepared meal company supported by a proprietary digital commerce platform designed to manage recurring customer relationships, online ordering and scalable fulfillment operations.

The acquisition represents an important milestone in Tritent’s strategy of acquiring established operating businesses with scalable business models, recurring revenue potential, proprietary technology and experienced leadership.

Following closing, Super Fresh Foods Inc. will become an indirect wholly owned subsidiary of Tritent International Corp., adding an operating subscription business with years of commercial experience and proprietary digital infrastructure designed to support long-term growth.

Entering One of the Fastest Growing Segments of Food Commerce

Consumer demand for prepared meals, subscription services and direct-to-consumer food delivery continues to expand as consumers increasingly prioritize convenience, healthier eating and recurring purchasing.

According to Grand View Research, the global online food delivery market exceeded US$380 billion in 2024 and is expected to continue growing throughout the coming decade.

At the same time, Fortune Business Insights estimates the global meal-kit and prepared meal delivery market will continue to experience strong growth as consumers increasingly adopt subscription-based purchasing models and recurring home delivery.

Management believes these trends are driving a structural shift toward recurring digital food commerce, creating attractive opportunities for businesses capable of combining food production, technology and customer engagement within a scalable operating platform.

An Operating Business Built Around Recurring Revenue

Unlike traditional food ordering marketplaces, AllYourMeals.com has been developed as a subscription-based prepared meal business supported by proprietary digital commerce technology.

While customers may place individual orders, the Company’s core business model emphasizes recurring meal subscriptions designed to create long-term customer relationships and recurring revenue.

The business combines an established prepared meal operation with a proprietary digital commerce platform supporting:

  • Subscription management
  • Recurring customer ordering
  • One-time purchases
  • Customer acquisition
  • Customer communications
  • Menu management
  • Production planning
  • Order management
  • Packing and fulfillment
  • Delivery coordination

Management believes this integrated operating model provides a scalable foundation for future expansion while allowing the Company to continuously improve operational efficiencies and customer experience.

More Than a Concept—An Established Operating Business

Management believes one of the most compelling aspects of this acquisition is that Tritent is acquiring an established operating business rather than an early-stage concept.

Super Fresh Foods has accumulated years of operational experience serving customers through its prepared meal business while continually refining its technology platform, production processes and customer engagement model.

The Company believes this operating history provides a meaningful foundation upon which to pursue future growth initiatives.

Through the acquisition Tritent acquires substantially all operating assets associated with Super Fresh Foods and AllYourMeals.com, including those conveyed under the transaction documents, such as intellectual property, proprietary software, databases, trademarks, domain names, websites, social media assets, customer-related assets and associated goodwill.

Leadership with Entrepreneurial Vision

The acquisition also brings the operating and entrepreneurial experience of Benny Doro, founder of Super Fresh Foods Inc. and All Your Meals.

Doro has led the development of the Company’s subscription-based direct-to-consumer prepared meal business while overseeing the creation of its proprietary digital commerce, customer management and fulfillment platform.

Management believes his operational experience and industry knowledge will play an important role in the continued growth of the business.

Creating Long-Term Shareholder Value

Tritent believes the acquisition creates multiple opportunities for future growth, including:

Expansion of digital food commerce services;

Strategic partnerships with restaurants and food brands;

Increased consumer engagement through technology;

Development of recurring revenue opportunities;

International expansion initiatives; and

Additional acquisitions that complement the Company’s growing portfolio.

The Company believes the addition of an operating digital platform further diversifies its business while creating opportunities to expand revenues through multiple complementary channels.

A Foundation for Future Growth

“This acquisition represents another important milestone in Tritent’s long-term growth strategy,” said Reno J. Calabrigo, Chief Executive Officer of Tritent International Corp.

“We’re excited to welcome Benny and the All Your Meals team to Tritent. What attracted us to this opportunity wasn’t simply a website—it was an established operating business with recurring customers, proprietary technology and years of operating experience. We believe businesses built around recurring revenue and scalable digital infrastructure represent compelling long-term opportunities, and this acquisition aligns well with Tritent’s strategy of building a diversified portfolio of operating companies capable of creating sustainable shareholder value.”

Benny Doro, Founder of Super Fresh Foods Inc., added:

“Joining Tritent gives us an opportunity to accelerate the growth of All Your Meals. We’ve spent years developing the operating experience behind the business and have built a subscription-based platform designed to support recurring customer relationships, ordering, production and fulfillment at scale. Tritent’s resources can help us accelerate the next stage of that growth while continuing to improve the experience we provide our customers.”

Looking Ahead

The Company expects to continue evaluating additional strategic acquisitions that complement its long-term vision of building a diversified portfolio of operating businesses with scalable revenue opportunities.

Management believes this acquisition represents another important step in Tritent’s long-term strategy of building a diversified portfolio of scalable operating businesses.

As the Company continues to execute this strategy, management expects to pursue opportunities that complement its existing operations while evaluating additional acquisitions, strategic partnerships and organic growth initiatives designed to strengthen the Company’s long-term competitive position.

About Tritent International Corp.

Tritent International Corp. (OTCID: TICJ) is focused on identifying, acquiring and developing businesses with scalable operating models, innovative technologies and long-term growth potential. Through disciplined acquisitions and strategic partnerships, the Company seeks to build a diversified portfolio of businesses designed to create sustainable long-term shareholder value.

About Super Fresh Foods Inc.

Super Fresh Foods Inc. is the owner and operator of AllYourMeals.com, a subscription-based prepared meal company supported by a proprietary digital commerce platform. The business combines recurring meal subscriptions, one-time ordering and technology designed to manage customer acquisition, subscription management, production planning, fulfillment and delivery. For additional information about Super Fresh Foods Inc., please visit:

Website: company.allyourmeals.com & allyourmeals.com

Forward-Looking Statements

This press release contains forward-looking statements regarding the anticipated benefits of the acquisition, future business plans, growth opportunities, industry trends and expected operating performance. These statements are based on current expectations and involve risks and uncertainties, including integration risks, market conditions, customer adoption, financing, competition, regulatory matters and other factors that could cause actual results to differ materially. Readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update these statements except as required by applicable law.

For more information, please contact:

Tritent International Corp.
Email: info@tritentintlcorp.com

Schouw & Co. share buy-back programme, week 40 2026

On 2 January 2026, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 59 of 18 December 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 240 million during the period 2 January to 31 December 2026. As outlined in Company Announcement no. 48 of 14 August 2026, the programme was extended with up to DKK 170 million, increasing the total amount of which Schouw & Co. will acquire shares to up to DKK 410 million.

The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).

Trading day No. of
shares
Average
price
Amount
DKK
   
Accumulated until 25 September 2026 470,041 705.04 331,398,272    
Monday, 28 September 2026 5,900 813.00 4,796,700    
Tuesday, 29 September 2026 5,500 807.27 4,440,000    
Wednesday, 30 September 2026 5,000 804.50 4,022,500    
Thursday, 1 October 2026 5,000 790.21 3,951,027    
Friday, 2 October 2026 5,000 799.04 3,995,208    
In the period 28 September 2026 – 2 October 2026 26,400 803.24 21,205,435    
Accumulated until 2 October 2026 496,441 710.26 352,603,707    
           
Following the above transactions, Schouw & Co. holds a total of 2,794,234 treasury shares corresponding to 11.18% of the total share capital of 25,000,000 shares.    
   

Aktieselskabet Schouw & Co.

Jørgen Dencker Wisborg, Chairman
Jens Bjerg Sørensen, President, telephone number +45 86 11 22 22

Attachments

AS Nordecon group company Embach Ehitus OÜ and the Estonian University of Life Sciences have entered into a contract for the design and reconstruction of blocks 3 and 5 of the academic building at Kreutzwaldi 56 in Tartu. The contract value is EUR 5.6 million, excluding VAT. The works are scheduled for completion in November 2027.

Nordecon (www.nordecon.com) is a group of construction companies whose core business is construction project management and general contracting in the buildings and infrastructures segment. Geographically the Group operates in Estonia, Ukraine and Sweden. The parent of the Group is Nordecon AS, a company registered and located in Tallinn, Estonia. The consolidated revenue of the Group in 2025 was 208 million euros. Currently Nordecon Group employs 450 people. Since 18 May 2006 the company’s shares have been quoted in the main list of the Nasdaq Tallinn Stock Exchange.

Andri Hõbemägi
Nordecon AS
Head of Investor Relations
Tel: +372 6272 022
E-mail: andri.hobemagi@nordecon.com
www.nordecon.com

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1 Details of the person discharging managerial responsibilities (PDMR)/person closely associated with them (PCA)
a) Name William Roberts
2 Reason for the notification
a) Position/status Non-Executive Director/PDMR
b) Initial notification/Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Admiral Group plc
b) LEI 213800FGVM7Z9EJB2685
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Identification code

Ordinary Shares

GB00B02J6398

b) Nature of the transaction Acquisition of shares pursuant to a dividend reinvestment trading plan entered into on 25 May 2022.
c) Prices(s) and volume(s) Price(s) Volume(s)
USD$48.66 206
d) Aggregated information

  • Aggregated value
  • Price
N/A (Single Transaction)
e) Date of the transaction 2 October 2026
f) Place of the transaction New York Stock Exchange (NYSE)

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.